Amendment No. 1 to the Sarepta Therapeutics, Inc. 2014 Employment Commencement Incentive Plan (June 28th, 2017)
WHEREAS, Sarepta Therapeutics, Inc. (the Company) previously adopted and approved the 2014 Employment Commencement Incentive Plan (the Plan) as an inducement stock plan under Nasdaq Stock Market Rule 5635(c)(4) to, among other things, attract and retain the best candidates for positions of substantial responsibility upon whose judgment, interest, and special effort the successful conduct of the Companys operation will be largely dependent; and
5,020,921 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (September 23rd, 2016)
2,102,000 Shares Sarepta Therapeutics, Inc. Common Stock ($0.0001 Par Value) EQUITY UNDERWRITING AGREEMENT (June 10th, 2016)
A Delaware Corporation Incorporated on June 5, 2013 Common Stock Par Value: $0.0001 (June 6th, 2013)
THIS CERTIFIES THAT is the record holder of (* *) fully paid and nonassessable shares of Common Stock, $0.0001 par value, of Sarepta Therapeutics, Inc., a Delaware corporation (the Corporation), transferable on the books of the Corporation, in person, or by duly authorized attorney upon surrender of this Certificate properly endorsed. This Certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar.
May 9, 2013 Michael A. Jacobsen (May 9th, 2013)
As we have recently discussed, the Compensation Committee (the Committee) of the Board of Directors of Sarepta Therapeutics, Inc. (the Company) approved a retention and severance benefits package for you. This letter summarizes the benefits approved by the Committee and sets forth the terms and conditions for you to receive the approved benefits.
Separation Agreement & General Release (March 1st, 2013)
THIS SEPARATION AGREEMENT & GENERAL RELEASE ("Agreement") is made and entered into by and between DAVID T. "TY" HOWTON ("Employee") and VERTEX PHARMACEUTICALS INCORPORATED (the "Company") as of the Effective Date (as such term is defined in Section 12 below).